Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) welcomes preliminary results which demonstrate the first-time restoration of normal pre-disease blood flow for its DurAVR™ transcatheter heart valve (THV) technology.
The technology performed favourably when compared to other transcatheter aortic valve replacements (TAVRs) and surgical aortic valve replacements (SAVRs) at six months.
Results unveiled at conference
The results have been presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the world's foremost meeting of interventional cardiologists, which is being held in Boston.
In a study of 22 patients comparing valve flow among current aortic valve replacement technologies, Anteris demonstrated no significant difference to the normal healthy aortic valve’s flow with DurAVR™ THV.
When current generation TAVR and SAVR valves were compared to the healthy aortic valve, both groups demonstrated statistically significant worse flow.
“This exciting data continues to demonstrate that by shaping the leaflets to mimic the native aortic valve, not only do we achieve superior haemodynamic performance but also restore normal laminar flow which is now demonstrated for the first time,” said Anteris CMO Dr Chris Meduri.
“Although preliminary, this data is remarkable and encouraging because it depicts a valve prosthesis, DurAVR™ THV, providing flow dynamics equal to that of a typical healthy native valve and is superior to current generation TAVR and SAVR haemodynamics,” said CEO Wayne Paterson.
Shares have been almost 5.3% higher in early trading to A$26.85.
About Anteris Technologies
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is a structural heart company focused on developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.
Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of younger and more active aortic stenosis patients by delivering durability, with innovations designed to last the remainder of a patient’s lifetime.